RYTM Q2 2021 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$274,000

Gross Profit

$137,00050.0% margin

Operating Income

-$40M-14756.2% margin

Net Income

-$35M-12915.7% margin

EPS (Diluted)

$-0.70

QoQ Revenue Growth

+682.9%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$37M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$388M

Total Liabilities

$37M

Stockholders' Equity

$352M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$274,000	$0	—
Gross Profit	$137,000	$0	—
Operating Income	-$40M	-$32M	-26.7%
Net Income	-$35M	-$31M	-13.7%